Holding(s) in Company

RNS Number : 9441F

Verona Pharma PLC

23 May 2017

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESⁱ


1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ⁱⁱ		Verona Pharma plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify): Change to notifiable interest following share issue.			X
3. Full name of person(s) subject to the notification obligation: ⁱⁱⁱ	Abingworth LLP Abingworth Bioventures VI LP
4. Full name of shareholder(s) (if different from 3.):^iv	State Street (Nominees) Limited (as nominee for Abingworth Bioventures V LP)
5. Date of the transaction and date on which the threshold is crossed or reached: ^v	19 May 2017
6. Date on which issuer notified:	22 May 2017
7. Threshold(s) that is/are crossed or reached: ^{vi, vii}	Downward crossing of the 7%, threshold

8. Notified details: Abingworth LLP

A: Voting rights attached to shares ^{viii, ix}

Class/type of
shares

if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of voting rights ^x

Direct

Direct ^xi

Indirect ^xii

Direct

Indirect

Verona Pharma plc

GB00B06GSH43

5p Ords

3,510,553

3.36%

Verona Pharma plc US9250501064

ADSs

3,705,000

3.54%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date ^xiii

Exercise/
Conversion Period ^xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ^{xv, xvi}

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date ^xvii

Exercise/
Conversion period ^xviii

Number of voting rights instrument refers to

% of voting rights ^{xix, xx}

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

7,215,553

6.90%

8. Notified details: Abingworth Bioventures VI LP

A: Voting rights attached to shares ^{viii, ix}

Class/type of
shares

if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of voting rights ^x

Direct

Direct ^xi

Indirect ^xii

Direct

Indirect

Verona Pharma plc

GB00B06GSH43

5p Ords

3,510,553

3.36%

Verona Pharma plc US9250501064

ADSs

3,750,000

3,705,000

3.54

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date ^xiii

Exercise/
Conversion Period ^xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ^{xv, xvi}

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date ^xvii

Exercise/
Conversion period ^xviii

Number of voting rights instrument refers to

% of voting rights ^{xix, xx}

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

7,215,553

6.90%

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: ^xxi

Abingworth Bioventures VI LP (which holds 7,215,553 shares in the company (6.90%)) is managed by Abingworth LLP.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease
to hold:

12. Date on which proxy holder will cease to hold
voting rights:

13. Additional information:

14. Contact name:

John Heard

15. Contact telephone number:

020 7534 1500

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLPGUGCAUPMUMW